P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

June 2009

Features

Health Policy

President Obama’s Health Care Reform Policies

Issues of Interest to P&T Committees

Increasing generic drug use, legalizing drug reimportation, establishing electronic health records, and using comparative effectiveness research to a greater extent are possible changes that might take place under the new administration.
C. Lee Ventola, MS

Safety and Efficacy of Red Yeast Rice (Monascus purpureus) as an Alternative Therapy for Hyperlipidemia

Red yeast rice is a dietary supplement with the same chemical structure as ­lovastatin (Mevacor), but it is not regulated by the FDA. Although patients have used it to reduce cholesterol levels, some serious problems (muscular atrophy, rhabdomyolysis) can result. Inconsistent quality and toxigenic ingredients can cause additional complications.
Matthew Klimek, PharmD, Shan Wang, PharmD, and Adeleye Ogunkanmi, PharmD

Meeting Highlights

American Society of Hypertension & American Urological Association

Some of the topics covered at the ASH sessions were fixed-dose combinations (Lotrel, Lotensin, Benicar HCT, and Azor) as well as an endothelin receptor agonist (darusentan). Therapies presented at the AUA meeting included dutasteride (Avodart) for reducing the risk of prostate cancer; a topical gel of oxybutynin chloride (Gelnique) for treating patients with overactive bladder; and silodosin (Rapaflo) for decreasing symptoms of benign prostatic hyperplasia.
Walter Alexander

Pharmaceutical Approval Update

Golimumab (Simponi) for the treatment of arthritis, Benzyl Alcohol Lotion 5% for patients with head lice, and artemether/lumefantine (Coartem/Riamet) tablets for uncomplicated malaria are discussed.
Marvin M. Goldenberg, PhD, RPh, MS

Section Two

Product Profiler: Immune Globulin Subcutaneous (Human) (Vivaglobin®)

For the Treatment of Primary Immunodeficiency Diseases

Section Three

Product Profiler: Immune Globulin Intravenous (Human), 10% Liquid (Privigen®)

For the Treatment of Primary Immunodeficiency Diseases

Departments

Editorial

You Get What You Pay For

David B. Nash, MD, MBA, describes survey results indicating that when it comes to improving health care, the old adage still applies: what gets paid for gets accomplished.
David B. Nash, MD, MBA

Medication Errors

A Patient’s Wandering Eye and the Internet Can Lead to Pump Tampering

Matthew Grissinger, RPh, FASCP, warns about the ­dangers of patients tampering with infusion pumps in the hospital.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Brand-Name Generic Deals Face End of the Line

Congress Likely to Ban Exclusion Payments

Stephen Barlas discusses ­possible legislation that might limit the ability of brand-name drug companies to delay the introduction of generic competitors.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Creon to testosterone gel, P&T presents the latest studies about FDA approvals, new indications, alerts, and industry updates.

Drug Forecast

Cinryze, a Human Plasma-Derived C1 Esterase Inhibitor for Prophylaxis of Hereditary Angioedema

The authors review a C1 esterase inhibitor, Cinryze, for prophylaxis against hereditary angioedema attacks.
Craig Cocchio, PharmD, and Nino Marzella, BS, MS, PharmD